Sign In
Buy STOK
$28.86
-1.18 (-3.93%)
At Close: Jul 31, 2026
Stoke Therapeutics Announces Proposed Public Offering
04:07pm, Tuesday, 26'th Mar 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?
07:54am, Tuesday, 26'th Mar 2024
Stoke Therapeutics (NASDAQ: STOK ) stock is soaring higher on Tuesday after the early-stage biopharmaceutical company posted positive clinical trial results. The new data comes from two open-label Ph
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
06:10pm, Monday, 25'th Mar 2024
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
04:01pm, Monday, 25'th Mar 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
09:51am, Thursday, 29'th Feb 2024
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Monday, 26'th Feb 2024
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
01:37pm, Sunday, 25'th Feb 2024
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the
Triple Threat: 3 Stocks to Buy for 3X Upside Potential
02:31pm, Monday, 19'th Feb 2024
You want speculative stocks with upside potential up to 3X returns? I'm going to give them to you.
Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?
10:56am, Thursday, 15'th Feb 2024
The mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?
08:01am, Thursday, 15'th Feb 2024
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
New Strong Buy Stocks for February 14th
06:50am, Wednesday, 14'th Feb 2024
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:30pm, Thursday, 04'th Jan 2024
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Wall Street Analysts Predict a 220.81% Upside in Stoke Therapeutics, Inc. (STOK): Here's What You Should Know
11:16am, Thursday, 14'th Dec 2023
The consensus price target hints at a 220.8% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Stoke Therapeutics Is Unable To Derisk Its Platform
05:08pm, Sunday, 10'th Sep 2023
Stoke Therapeutics (STOK) stock is down 40% after failing to meet expectations in a phase 1/2 epilepsy trial. STOK develops therapies for rare diseases using its TANGO approach, but its high valuation
